A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Arcus Biosciences, Inc.
AstraZeneca
Merck Sharp & Dohme LLC
Incyte Corporation
Toray Industries, Inc
ImmunityBio, Inc.
AstraZeneca
Valerio Therapeutics